Trials / Unknown
UnknownNCT04943718
Personalized Vaccine for Patients With Recurrent Malignant Glioma
Personalized Vaccine for Patients With Recurrent Malignant Glioma: a Single-arm, Single-center, Open-labeled Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Xuanwu Hospital, Beijing · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A single-arm, single-center, open-labeled study will be conducted with an aim to investigate the feasibility, safety, and efficacy of the personalized vaccine for patients with recurrent malignant glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | personalized vaccine | Based on genetic and transcriptional sequencing information, personalized peptide vaccines would be designed and produced; patients would be vaccinated on day 1, 4, 8 ,15, 22 and then on week 12, 20. |
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2023-06-13
- Completion
- 2024-06-13
- First posted
- 2021-06-29
- Last updated
- 2021-06-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04943718. Inclusion in this directory is not an endorsement.